The global clinical microbiology market size is projected to reach USD 5.3 billion by 2025 from USD 3.9 billion in 2020, at a CAGR of 6.5%
Factors such as the technological advancements in the market are propelling the growth of the clinical microbiology market. Additionally, rising inclination epidemics like COVID-19 and investments from private and public sectors affect the growth of clinical microbiology market.
New York, Oct. 21, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Clinical Microbiology Market by Application, Disease, Product, End User – Global Forecast to 2025” – https://www.reportlinker.com/p03887589/?utm_source=GNW
However, unfavorable reimbursement scenarios in some countries is hampering the growth of this market.
The recent COVID-19 global pandemic has also impacted the clinical microbiology market.Demand from the main end-users has declined as key regions, and countries have imposed social distancing rules and lockdowns.
This impact is expected to be short-term, and no adverse effects are to be foreseen after the market gradually reopens.
The reagent segment to witness the highest growth rate in the clinical microbiology market, by product, during the forecast period.
The reagent segment is expected to witness the highest growth rate during the forecast period. The high growth in this owes to the high prevalence of infectious diseases across major markets (resulting in a growing number of clinical diagnostic procedures), the increasing trend of reagent rental agreements along with instrument sales, and a rising number of life science researches in the field of specific reagents for targeted infectious disease diagnosis and treatment, especially across emerging countries.
The respiratory diseases accounted for the largest share of the clinical microbiology market, by diseases, in 2019.
The respiratory diseases segment accounted for the largest share of the clinical microbiology market in 2019.This segment is also estimated to register the highest CAGR during the forecast period.
The large share and high growth rate of this segment can be attributed to factors such as the large patient population suffering from respiratory diseases, rising prevalence of target respiratory diseases (such as TB, asthma, COPD, and bronchitis) across developing countries, and growth in the number of epidemic outbreaks of respiratory infections.
The hospitals & diagnostics centers segment accounted for the largest share of the clinical microbiology, by end-users, in 2019
The hospitals and diagnostic centers segment accounted for the largest market share in 2019. The large share of this segment is attributed to the high incidence of target diseases (such as tuberculosis, HIV-AIDS, malaria, and epidemic diseases), availability of technologically advanced products (such as molecular diagnostic products and PCR and NGS-based instruments) for infectious disease diagnosis, growing awareness among doctors and clinicians regarding the advantages offered by molecular diagnostic products for fast and effective disease diagnosis, and ongoing expansion of healthcare infrastructure across emerging countries.
The Asia Pacific market to grow at the highest CAGR during the forecast period.
The clinical microbiology market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Government efforts to increase awareness related to genome-based infectious disease diagnosis, supportive regulations for the development and commercialization of advanced clinical microbiology products, rising healthcare expenditure, an increasing number of hospitals and
Purdue Pharma, the manufacturer of the prescription painkiller OxyContin, reached an $8 billion settlement with the Department of Justice and will plead guilty to three federal criminal charges in connection with its role in America’s opioid crisis.
The Justice Department announced on Wednesday that it had reached a resolution in its investigation into individual shareholders from the Sackler family, who own the pharmaceutical company.
Purdue Pharma will plead guilty in a New Jersey federal court to three felony counts, including one count of dual-object conspiracy to defraud the United States and to violate the Food, Drug, and Cosmetic Act, and two counts of conspiracy to violate the Federal Anti-Kickback Statute.
The deal does not release the company’s executives or owners from criminal liability and a criminal investigation is ongoing.
“The abuse and diversion of prescription opioids has contributed to a national tragedy of addiction and deaths, in addition to those caused by illicit street opioids,” Deputy Attorney General Jeffrey Rosen said in the announcement. “With criminal guilty pleas, a federal settlement of more than $8 billion, and the dissolution of a company and repurposing its assets entirely for the public’s benefit, the resolution in today’s announcement re-affirms that the Department of Justice will not relent in its multi-pronged efforts to combat the opioids crisis.”
According to the Justice Department, the resolution includes the largest penalties ever levied against a pharmaceutical company and includes a criminal fine of $3.544 billion, an additional $2 billion in criminal forfeiture and a $2.8 billion civil settlement.
Separately, the Sackler family has agreed to pay $225 million in damages.
A Rebirth Behind Bars
Steve Miller, who became chairman of the company’s board in 2018, said in a press release that the company “deeply regrets and accepts responsibility for the misconduct detailed by the Department of Justice.”
The company filed for bankruptcy last year as it wades through thousands of civil lawsuits. As part of the resolution, Purdue Pharma would cease to operate in its current form and would instead transition to a public benefit company owned by a trust or similar entity. The new company would be operated under different ownership and “will work to provide for free or at cost millions of doses of lifesaving opioid addiction treatment and overdose reversal medicines,” the press release stated.
– The increasing demand for non-invasive testing methodologies and rising chronic disease incidence are driving the demand for the market.
– Market Size – USD 3.80 billion in 2019, Market Growth – CAGR of 26.2%, Market Trends – Rise in the use of Cell-Free DNA (cfDNA) Testing to treat chromosomal disorders.
VANCOUVER, BC, Oct. 20, 2020 /PRNewswire/ — The Global Cell-Free DNA (cfDNA) Testing Market is forecast to be worth USD 22.41 Billion by 2027, according to a new report by Emergen Research. The Global Cell-Free DNA (cfDNA) Testing Market is projected to grow significantly during the forecast period due to increased incidences of cancers, rising prevalence of chromosome abnormalities in babies due to an increasing number of late pregnancy, and growing demand for non-invasive testing procedures. Moreover, increasing investments by governments to implement advanced therapeutic technology in hospitals is also expected to boost the market during the forecast period.
However, expensive equipment and a lack of skilled healthcare professionals would restrain the market growth in the forecast timeframe.
Request free sample of this research report at: https://www.emergenresearch.com/request-sample/156
Key Highlights From The Report
In August 2019, Agilent Technologies Inc. announced the acquisition of a leading manufacturer of innovative healthcare equipment, BioTek Instruments, Inc. This acquisition will expand Agilent’s product portfolio and its presence in North America.
Cell-free fetal DNA is a non-invasive procedure and, therefore, does not pose a health risk of CVS (chorionic villus sampling) or amniocentesis, like pain and any slight chance of infection. Due to these benefits, the cell-free fetal DNA segment held the largest market share of 48.8% in the Global Cell-Free DNA (cfDNA) Testing Market in 2019.
The MPSS technology segment is estimated to dominate the global market with a CAGR of 26.7%, owing to the advantage of producing a measurable profile of gene expression in cells or tissues.
The gynecology segment is anticipated to lead the market during the forecast period, as the cell-free DNA approach is being used to detect genetic issues of baby and to diagnose pregnancy complications such as pregnancy loss.
North America accounted for the largest market share of around 33.6% in 2019, owing to the increasing chronic diseases and pregnancy problems in this region due to the changing lifestyles. Besides, the adoption of advanced technology in hospitals is also expected to boost the market shortly.
Key participants include Sequenom, Inc., Quest Diagnostics, Illumina Inc., Agilent Technologies, Inc., Guardant Health, Inc., Biodesix, Inc., Allenex AB, Roche Holdings AG, Biocept, Inc., and CareDx, Inc., among others.
To get leading market solutions, visit the link below: https://www.emergenresearch.com/industry-report/cell-free-dna-market
Emergen Research has segmented the Global Cell-Free DNA (cfDNA) Testing Market on the basis of type, technology, application, and region:
Type Outlook (Revenue, USD Billion; 2017-2027)
Technology Outlook (Revenue, USD Billion; 2017-2027)
Application Outlook (Revenue, USD Billion; 2017-2027)
Order Now: https://www.emergenresearch.com/select-license/156
Find more similar research insights by Emergen Research:
Wound Cleanser Products Market By Product Type (Wetting Agents, Antiseptics, Moisturizers, Others), By Form Type (Sprays, Solutions, Wipes, Foams, Others), By End
The United Nations said Monday it would stockpile one billion syringes around the world by the end of 2021, to be used for the delivery of any future coronavirus vaccine.
UNICEF, the UN Children’s Fund, said it aims to get 520 million syringes in its warehouses by the end of this year, to guarantee an initial supply in countries ahead of the vaccine.
“The world will need as many syringes as doses of vaccine,” UNICEF said in a statement.
UNICEF said it was also buying five million safety boxes for used syringes.
The number of confirmed coronavirus cases worldwide passed 40 million on Monday, according to an AFP tally based on official sources. More than 1.1 million deaths have been recorded across the globe.
“Vaccinating the world against Covid-19 will be one of the largest mass undertakings in human history, and we will need to move as quickly as the vaccines can be produced,” said UNICEF executive director Henrietta Fore.
“By the end of the year, we will already have over half a billion syringes pre-positioned where they can be deployed quickly and cost effectively.”
The syringes will be used by Covax, the international coronavirus vaccine procurement, production and distribution pool created by the World Health Organization (WHO).
Covax is run by the Gavi vaccine alliance, which will reimburse UNICEF for the syringes.
A public-private partnership, Gavi helps vaccinate half the world’s children against some of the deadliest diseases on the planet.
Syringes have a five-year shelf life and tend to be shipped by sea, rather than vaccines, which are heat-sensitive and transported more quickly by air freight.
The billion syringes come on top of the 620 million that UNICEF would purchase for other vaccination programmes against diseases such as measles and typhoid.
The WHO says 42 vaccine candidates are currently being tested on humans, of which 10 have reached the mass testing third and final stage.
A further 156 are being worked on in laboratories in preparation for human testing.
Typically, only around 10 percent of vaccine candidates make it through the trials.
Global Monoclonal Antibodies Market to Surpass US$ 368.8 Billion by 2027, Says Coherent Market Insights (CMI)
According to Coherent Market Insights, the global monoclonal antibodies market is estimated to be valued at US$ 143.5 billion in 2020 and is expected to exhibit a CAGR of 14.4% over the forecast period (2020-2027).
Key Trends and Analysis of the Global Monoclonal antibodies Market:
Key trends in the market include increasing prevalence of cancer, rising regulatory approvals and launch of therapies, increasing research collaborations for the development of robust drugs pipeline, and adoption of collaboration strategies by the companies.
Rising incidence of cancer is expected to increase demand for infusion therapies, thereby contributing to significant growth of the monoclonal antibodies market. For instance, according to the World Cancer Research Fund International’s report, in 2018, breast cancer accounted for the second highest number of cancer cases worldwide, accounting for 2,088,849 new cases worldwide in 2018.
Moreover, increasing research collaborations for the development of robust drugs pipeline is a major factor that is expected to drive the market growth over the forecast period. Success of popular monoclonal antibodies such as Avastin, Herceptin, and Rituxan (revenue as US$ 6.8 Bn, US$ 7.1 Bn, and US$ 5.9 Bn, respectively in 2017 globally) has spurred manufacturers’ interest in these therapies. For instance, in 2018, Novartis AG announced entering into a partnership with MorphoSys and Galapagos for the commercialization and development of human immunoglobulin G1 (IgG1) monoclonal antibody targeting interleukin (IL)-17C.
Rising number of product approvals is expected to drive the market growth. For instance, in March 2019, AbbVie announced receiving approval for SKYRIZI (risankizumab) from Japanese Ministry of Health, Labour and Welfare (MHLW). Also, in March 2019, the U.S. FDA approved Trazimera (trastuzumab-gyyp) for the treatment of metastatic gastric adenocarcinoma and HER2 positive breast cancer.
Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2403
Key Market Takeaways:
The global monoclonal antibodies market is expected to exhibit a CAGR of 14.4% over the forecast period, owing to adoption of collaboration strategy by the market players, which is expected to drive the market growth. For instance, in July 2020, UCB announced a license agreement with Roche and Genentech for the development and commercialization of UCB0107, an investigational monoclonal antibody drug, which is a potential treatment for patients with progressive supranuclear palsy (PSP) and Alzheimer’s disease.
An increasing number of government initiatives and funding for clinical trials of drugs, which can be used in the Covid-19 treatment, is projected to favor the market growth. For instance, in March 2020, the World Health Organization launched the ‘Solidarity’ trial, which is a multinational initiative for testing old and new drugs/therapies for treating Covid-19. The trial includes testing four therapies; remdesivir, chloroquine and hydroxychloroquine, lopinavir and ritonavir, lopinavir with ritonavir and interferon-beta.
Key players operating in the global monoclonal antibodies market include Pfizer Inc., Novartis AG, Bayer AG, Sanofi S.A., F. Hoffmann-La Roche AG, Eli Lilly and Co., Merck & Co., Inc., GlaxoSmithKline Plc., AbbVie Inc., Bristol-Myers Squibb, and Regeneron Pharmaceuticals Inc.
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/2403
Global Monoclonal Antibodies Market, By Source: